Is a universal, one dose cholera vaccine possible?

Open Vaccine Journal

Volumn 4, Issue 1, 2011, Pages 18-30

  Wade, William F ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

B cells; Cholera; Cholera vaccine; System biology

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; KILLED WHOLE CELL CHOLERA VACCINE; LIVE CHOLERA VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL GENE; CHOLERA; DRUG EFFICACY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIBRIO CHOLERAE;

EID: 84856617297     PISSN: None     EISSN: 18750354     Source Type: Journal    
DOI: 10.2174/1875035401104010018     Document Type: Article

References (114)

1. Cholera vaccines: WHO position paper Wkly Epidemiol Rec, 2010, 85(13), 117-128.
2. Nelson, E.J.; Chowdhury, A.; Flynn, J.; Schild, S.; Bourassa, L.; Shao, Y.; LaRocque, R.C.; Calderwood S.B.; Qadri F; Camilli A. Transmission of Vibrio cholerae is antagonized by lytic phage and entry into the aquatic environment: PLoS Path, 2008, 10, e1000187.
3. Kamruzzaman, M.; Udden, S.M.; Cameron, D.E.; Calderwood, S.B.; Nair, G.B.; Mekalanos, J. J.; Faruque, S. M. Quorumregulated biofilms enhance the development of conditionally viable: environmental Vibrio cholerae. Proc Natl Acad Sci USA, 2010, 107(4), 1588-1593.
4. Matson, J.S.; Withey, J.H.; DiRita, V.J. Regulatory networks controlling Vibrio cholerae virulence gene expression. Infect Immun, 2007, 75(12), 5542-5549.
5. Pruzzo, C.; Vezzulli, L.; Colwell, R.R. Global impact of Vibrio cholerae interactions with chitin. Environ Microbiol, 2008,10(6), 1400-1410.
6. Ryan, E.T.; Calderwood, S.B. Cholera vaccines. Clin Infect Dis, 2000, 31(2), 561-565.
7. Bishop, A. L.; Camilli, A. Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines. 2011, 10(1), 79-94.
8. Levine, MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010, 4, 8, 129.
9. Chowdhury, M.I.; Sheikh, A.; Qadri, F. Development of Peru-15 (Cholera Garde), a live-attenuated oral cholera vaccine: 1991-2009. Expert Rev Vaccines. 2009, 8(12), 1643-52.
10. Lopez, A.L.; Clemens, J.D.; Deen, J.; Jodar, L. Cholera vaccines for the developing world. Hum Vaccin. 2008, 4(2),165-169.
11. Ritchie, J.M.; Waldor, M.K. Vibrio cholerae interactions with the gastrointestinal tract: lessons from animal studies. Curr Top Microbiol Immunol. 2009, 337, 37-59.
12. Benenson, A.; Joseph, P.R.; Oseasohn, R.O. Cholera vaccine field trials in East Pakistan: Reaction and antigenicity studies. Bull World Health Org, 1968, 38(3), 347-357.
13. Benenson, A.; Mosley, W.H.; Fahimuddin, M.; Oseasohn, R.O. Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field. Bull World Health Org, 1968, 38(3), 359-372.
14. Mosley, W. H.; Woodward, W. E.; Aziz, K. M.; Rahman, A. S.; Chowdhury, A. K.; Ahmed, A.; Feeley, J. C.; The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen; with comparative results of serological and animal protection tests. J Infect Dis, 1970, 121(suppl), 1-9.
15. Graves, P.M.; Deeks, J.J.; Demicheli, V.; Jefferson T. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected). Cochrane Database Syst Rev, 2010, 8, CD000974.
16. Tacket, C.O.; Cohen, M.B.; Wasserman, S.S.; Losonsky, G.; Livio, S.; Kotloff, K.; Edelman, R.; Kaper, J. B.; Cryz, S. J.; Giannella, R. A.; Schiff, G.; Levine, M. M. Randomized, double-blind, placebocontrolled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor Inaba three months after vaccination. Infect Immun, 1999, 67(12), 6341-6345.
17. Gupta, R.K.; Taylor, D.N.; Bryla, D.A.; Robbins, J.B.; Szu, S.C. Phase 1 evaluation of Vibrio cholerae O1; serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun, 1998, 66(7), 3095-3099.
18. Kirn, T.J.; Jude, B.A.; Taylor, R.K. A colonization factor links Vibrio cholerae environmental survival and human infection. Nature, 2005, 438(7069), 863-866.
19. Osek, J.; Jonson, G.; Svennerholm, A.M.; Holmgren, J. Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun, 1994, 62(7), 2901-2907.
20. Knuf, M.; Habermehl, P.; Cimino, C.; Petersen, G.; Schmitt, H. J. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine [PCV7] concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine, 2006, 24(22), 4727-4736.
21. Guentzel, M.N.; Berry, L.J. Protection of suckling mice from experimental cholera by maternal immunization: comparison of the efficacy of whole-cell, ribosomal-derived, and enterotoxin immunogens. Infect Immun, 1974, 10(1),167-172.
22. Guentzel, M.N.; Berry, L.J. Motility as a virulence factor for Vibrio cholerae. Infect Immun, 1975, 11(5), 890-597.
23. Eubanks, E.R., Guentzel, M.N., Berry, L.J. Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect Immun, 1977, 15(2), 533-538.
24. Guentzel, M.N.; Field, L.H.; Eubanks, E.R.; Berry, L.J. Use of fluorescent antibody in studies of immunity to cholera in infant mice. Infect Immun. 1977, 15(2), 539-548.
25. Bishop, A.L.; Schild, S.; Patimalla, B.; Klein, B.; Camilli, A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by anti-lipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun, 2010, 78(10), 4402-4420.
26. Huq, A.; Whitehouse, C.A.; Grim, C.J.; Alam, M.; Colwell, R.R. Biofilms in water, its role and impact in human disease transmission. Curr Opin Biotechnol, 2008, 19(x), 244-247.
27. Yildiz, F.H.; Visick, K.L. Vibrio biofilms: so much the same yet so different. Trends Microbiol, 2009, 17(3), 109-118.
28. Faruque; S.M.; Biswass, K.; Nashir-Udden, S.M.; Ahmad, Q.S.; Sack, D.A.; Nair, G.B.; Mekalanos, J.J. Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci USA, 2006, 103(16), 6350-6355.
29. Schild, S.; Tamayo, R.; Nelson, E.J.; Qadri, F.; Calderwood, S.B.; Camilli, A. Genes induced late in infection increase fitness of Vibrio cholerae after release into the environment. Cell Host Microbe, 2007, 2(4), 264-277.
30. Merrell, D.S.; Butler, S.M.; Qadri, F.; Dolganov, N.A.; Alam, A.; Cohen, M.B.; Calderwood, S.B.; Schoolnik, G.K.; Camilli, A. Host-induced epidemic spread of the cholera bacterium. Nature, 2002, 417(6889), 642-645.
31. Tamayo, R.B.; Patimalla, B.; Camilli, A. Growth in a biofilm induces a hyperinfectious phenotype in Vibrio cholerae. Infect Immun, 2010, 78(8), 3560-3569.
32. Osek, J.; Svennerholm, A.M.; Holmgren, J. Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili. Infect Immun, 1992, 60(11), 4961-4496.
33. Taylor, R.K.; Kirn, T.J.; Meeks, M.D.; Wade, T.K.; Wade, W.F. A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect Immun, 2004, 72(10), 6050-6060.
34. Lombardo, M.J.; Michalski, J.; Martinez-Wilson, H.; Morin, C.; Hilton, T.; Osorio, C.G.; Nataro, J.P.; Tacket, C.O.; Camilli, A.; Kaper, J.B. An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers. Proc Natl Acad Sci USA, 2007, 104(46), 18229-18234.
35. Alam, A.; Larocque, R.C.; Harris, J.B.; Vanderspurt, C.; Ryan, E.T.; Qadri, F.; Calderwood, S.B. Hyperinfectivity of humanpassaged Vibrio cholerae can be modeled by growth in the infant mouse. Infect Immun, 2005, 73(10), 6674-6649.
36. Larocque, R.C.; Harris, J.B.; Dziejman, M.; Li, X.; Khan, A.I.; Cohen, M.B.; Calderwood, S.B.; Schoolnik, G.K.; Camilli, A. Transcriptional profiling of Vibrio cholerae recovered directly from patient specimens during early and late stages of human infection. Infect Immun, 2005, 73(8), 4488-93.
37. Keymer, D.P.; Miller, M.C.; Schoolnik, G.K.; Boehm, A.B. Genomic and phenotype diversity of costal Vibrio cholerae strains is linked to environmental factors. Appl Environ Microbiol, 2007, 73(11), 3705-3714.
38. Butler, S.M.; Camilli, A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol, 2005, 3(8), 611-620.
39. LaRocque, R.C.; Krastins, B.; Harris, J.B.; Lebrun, L. M.; Parker, K.C.; Chase, M.; Ryan, E.T.; Qadri, F.; Sarracino, D.; Calderwood, S.B. Proteomic analysis of Vibrio cholerae in human stool. Infect Immun, 2008, 76(9), 4145-4151.
40. Osorio, C.G.; Martinez-Wilson, H; Camilli, A. The ompU paralogue vca1008 is required for virulence of Vibrio cholerae. J Bacteriol, 2004, 186(15), 5167-5171.
41. Wade, W.F.; O'Toole, G.A. Antibodies and immune effectors: shaping Gram-negative bacterial phenotypes. Trends Microbiol, 2010, 18(6), 234-239.
42. Coelho, A.; de Oliveira Santos, E.; Faria, M.L.; de Carvalho, D.P.; Soares, M.R.; von Kruger, W.M.; Bisch, P.M. A proteome reference map for Vibrio cholerae El Tor. Proteomics, 2004, 4(5), 1491-1504.
43. Hang, L.; John, M.; Asaduzzaman, M.; Bridges, E.A.; Vanderspurt, C.; Kirn, T.J.; Taylor, R.K.; Hillman, J.D.; Progulske-Fox, A.; Handfield, M.; Ryan, E.T.; Calderwood, S.B. Use of in vivoinduced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc Natl Acad Sci USA, 2003, 100(14), 8508-8513.
44. Taylor, R.K.; Miller, V.L.; Furlong, D.B.; Mekalanos, J.J. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci USA, 1987; 84(9), 2833-2837.
45. Attridge, S.R.; Manning, P.A.; Holmgren, J.; Jonson, G. Relative significance of mannose-sensitive hemagglutinin and toxincoregulated pili in colonization of infant mice by Vibrio cholerae El Tor. Infect Immun, 1996, 64(8), 3369-3373.
46. Fullner, K.J.; Mekalanos, J.J. Genetic characterization of a new type IV-A pilus gene cluster found in both classical and El Tor biotypes of Vibrio cholerae. Infect Immun, 1999, 67(3), 1393-1404.
47. Tacket, C.O.; Forrest, B.; Morona, R.; Attridge, S.R.; LaBrooy, J.; Tall, B.D.; Reymann, M.; Rowley, D.; Levine, M.M. Safety; immunogenicity; and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun, 1990, 58(6), 1620-1627.
48. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2011 MMWR, 2011, 60(5), 1-4.
49. Lanzavecchia, A.; Sallusto, F. Human B cell memory. Curr Opin Immunol, 2009, 21(x), 298-304.
50. Mage, R.G.; Lanning, D.; Knight, K.L. B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev Comp Immunol, 2006, 30(1-2), 137-153.
51. Brandtzaeg, P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest, 2010, 39(4-5), 303-355.
52. Strugnell, R.A.; Wijburg, O.L. The role of secretory antibodies in infection immunity. Nat Rev Microbiol, 2010, 8(9), 656-667.
53. Hooper, L.V.; Macpherson, A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol, 2010, 10(3), 159-169.
54. Amanna, I.J.; Slifka, M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev, 2010, 236, 125-138.
55. Ueno, H.; Schmitt, N.; Palucka, A.K.; Banchereau, J. Dendritic cells and humoral immunity in humans. Immunol Cell Biol, 2010, 88(4), 376-380.
56. Lee, S.M.; Jeon, S. T.; Suk, K.; Lee, W.H. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunol, 2010, 131(3), 350-356.
57. Khan, W.N. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol, 2009, 183(6), 3561-3567.
58. Mackay, F.; Schneider, P. Cracking the BAFF code. Nat Rev Immunol, 2009, 9(7), 491-502.
59. Yeramilli, V.A.; Knight, K.L. Requirement for BAFF and APRIL during B cell development in GALT. J Immunol, 2010, 184(10), 5527-5536.
60. Uematsu, S.; Fuijimotot, K.; Jang, M.; Yang, B.; Nishiyama, M.; Sato, S; Tsujimura, T.; Yamamoto, M.; Yokota, Y.; Kiyono, H.; Miyasaka, M.; Ishii, K.J.; Akira, S. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol, 2008, 9(7), 769-776.
61. Spencer, J.; Barone, F.; Dunn-Walters, D. Generation of Immunoglobulin diversity in human gut-associated lymphoid tissue. Semin Immunol, 2009, 21(3), 139-346.
62. Yoshida, T.; Mei, H.; Dörner, T.; Hiepe, F.; Radbruch, A.; Fillatreau, S.; Hoyer, B.F. Memory B and memory plasma cells. Immunol Rev, 2010, 237(1), 117-139.
63. Batista, F.D.; Harwood, N.E. The who; how and where of antigen presentation to B cells. Nat Rev Immunol, 2009, 9(1), 15-27.
64. Weill, J.C.; Weller, S.; Reynaud, C.A. Human marginal zone B cells. Annu Rev Immunol, 2009, 27, 267-285.
65. Suzuki, K.; Maruya, M.; Kawamoto, S.; Sitnik, K.; Kitamura, H.; Agace, W.W.; Fagarasan, S. The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity, 2010, 33(1), 71-83.
66. Suzuki, K.; Maruya, M.; Kawamoto, S.; Fagarasan, S. Roles of B-1 and B-2 cells in innate and acquired IgA-mediated immunity. Immunol Rev, 2010, 237(1), 180-190.
67. Goodnow, C.C.; Vinuesa, C.G.; Randall, K.L.; Mackay, F.; Brink, R. Control systems and decision making for antibody production. Nat Immunol, 2010, 11(8), 681-688.
68. MacLennan, I.C.; Toellner, K.M.; Cunningham, A.F.; Serre, K.; Sze, D.M.; Zúñiga, E; Cook, M.C.; Vinuesa, C.G. Extrafollicular antibody responses. Immunol Rev, 2003, 194, 8-18.
69. Endsley, M.A.; Njongmeta, L.M.; Shell, E.; Ryan, M.W.; Indrikovs, A.J.; Ulualp, S.; Goldblum, R.M.; Mwangi, W.; Estes D.M. Human IgA-inducing protein from dendritic cells induces IgA production by naive IgD+ B cells. J Immunol, 2009, 182(4), 1854-1859.
70. El Shik, h M. E; El Sayed, R.M.; Sukumar, S.; Szakal, A.K.; Tew, J. G Activation of B cells by antigens on follicular dendritic cells. Trends Immunol, 2010, 31(6), 205-211.
71. Pillai, S.; Cariappa, A.; Moran, S.T. Marginal zone B cells. Annu Rev Immuno, 2005, 23, 161-196.
72. Weller, S.; Faili, A.; Aoufouchi, S.; Guéranger, Q.; Braun, M.; Reynaud, C.A.; Weill, J.C. Hypermutation in human B cells in vivo and in vitro. Ann N Y Acad Sci, 2003, 987, 158-165.
73. Harris, A.M.; Bhuiyan, M.S.; Chowdhury, F.; Khan, A.I.; Hossain, A.; Kendall, E.A.; Rahman, A; LaRocque, R.C.; Wrammert, J.; Ryan, E.T.; Qadri, F.; Calderwood, S.B.; Harris, J.B. Antigenspecific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun, 2009, 77(9), 3850-3856.
74. Kendall, E.A.; Tarique, A.A.; Hossain, A.; Alam, M.M.; Arifuzzaman, M.; Akhtar, N.; Chowdhury, F.; Khan, A.I.; Larocque, R.C.; Harris, J.B.; Ryan, E.T.; Qadri, F.; Calderwood S.B. Development of immunoglobulin M memory to both a T-cellindependent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect Immun, 2010, 78(1), 253-259.
75. Chernyak, A.; Kondo, S.; Wade, T.K.; Meeks, M.D.; Alzari, P.M.; Fournier, J.M.; Taylor, R.K.; Kovác, P.; Wade, W.F. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis, 2002, 185(7), 950-962.
76. Wade, T.K.; Wade, W.F. Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains. Microbiol Immunol, 2008, 52(12), 611-620.
77. Oliver, A.M.; Martin, F.; Gartland, G.L.; Carter, R.H.; Kearney, J.F. Marginal zone B cells exhibit unique activation; proliferative and immunoglobulin secretory responses. Eur J Immunol, 1997, 27(9), 2366-2374.
78. Cerutti, A. Immunology. IgA changes the rules of memory. Science, 2010, 328(x), 1646-1647.
79. Hapfelmeier, S.; Lawson, M.A.; Slack, E.; Kirundi, J.K.; Stoel, M.; Heikenwalder, M.; Cahenzli, J.; Velykoredko, Y; Balmer, M.L.; Endt, K.; Geuking, M.B.; Curtiss, R. 3rd; McCoy, K.D.; Macpherson, A. J. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science, 2010, 328(5986), 1705-1709.
80. Enserink, M. Public health. No vaccines in the time of cholera. Science, 2010, 329(5998), 14621463.
81. Hartley, D.M.; Morris, J.G. Jr; Smith, D.L. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS Med, 2006, 3(1), e7.
82. Ali M.; Emch, M.; Yunus, M.; Sack, D.; Lopez, A.L.; Holmgren, J.; Clemens, J. Vaccine protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J, 2008, 27(1), 33-37.
83. Chao, D.L.; Halloran, M.E.; Longini, I.M.; Jr. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A, 2011, 108(17), 7081-7085.
84. Nielsen, A.T.; Dolganov, N.A.; Rasmussen, T.; Otto, G.; Miller, M.C.; Felt, S.A.; Torreilles, S.; Schoolnik, G.K. A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathol, 2010, 6(9). e1001102.
85. Seib, K.L.; Dougan, G.; Rappuoli, R. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet, 2009, 5(10), e1000612.
86. Taki, S.; Meiering, M.; Rajewsky, K. Targeted insertion of a variable region gene into the immunoglobulin heavy chain locus. Science, 1993, 262(5137), 1268-1271.
87. Velázquez, P.; Waite, J.C.; Dustin, M.L. Dynamics of host defense: the view at the front lines. Nat Immunol, 2007, 8(11), 1153-1157.
88. Sinclair, D.; Abba, K.; Zaman, K.; Qadri, F.; Graves, P.M. Oral vaccines for preventing cholera. Cochrane Database Syst Rev, 2011, 3:CD008603.
89. Cryz, S.J.; Jr.; Kaper, J.; Tacket, C.; Nataro, J.; Levine, M.M. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects. Dev Biol Stand, 1995, 84, 237-244.
90. Simanjuntak, C.H.; O'Hanley, P.; Punjabi, N.H.; Noriega, F.; Pazzaglia, G.; Dykstra, P.; Kay, B.; Suharyono; Budiarso, A.; Rifai, A.R.; Wasserman; S.S.; Losonsky; G.; Kaper; J. Cryz; S. Levine, M.M. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24-to 59-monthold Indonesian children. J Infect Dis, 1993, 168(5), 1169-1176.
91. Richie, E.E.; Punjabi, N.H.; Sidharta, Y.Y.; Peetosutan, K.K.; Sukandar, M. M.; Wasserman, S. S.; Lesmana, M. M.; Wangsasaputra, F.F.; Pandam, S.S.; Levine, M.M.; O'Hanley, P.P.; Cryz, S.J.; Simanjuntak, C.H. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine, 2000, 18(22), 2399-2410.
92. Clemens, J.D.; Sack, D.A.; Harris, J.R.; Van Loon, F.; Chakraborty, J.; Ahmed, F.; Rao, M.R.; Khan, M.R.; Yunus, M.; Huda, N.; Eeckels, R.; Clemens J.D.; Rao; M.F.; Eng, M.; Kay, B.A.; Sack; D.A.; Harris, J.R.; Stanton; B.F.; Walter; S.; Eeckels, R.; Svennerholm, A.-M.; Holmgren, J. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet, 1990; 335(8684), 270-273.
93. van Loon, F.P.; Clemens, J.D.; Chakraborty, J.; Rao, M.R.; Kay, B.A.; Sack, D.A.; Yunus, M.; Ali, M.; Svennerholm, A.M.; Holmgren, J. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine, 1996, 14(2), 162-166.
94. Anh, D.D.; Canh, D.G.; Lopez, A. L; Thiem, V.D.; Long, P.T.; Son, N.H.; Deen, J.; von Seidlein, L.; Carbis, R.; Han, S.H.; Shin, S.H.; Attridge, S.; Holmgren, J.; Clemens J. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine, 2007, 25(6), 1149-1155.
95. Trach, D.D.; Clemens, J.D.; Ke, N.T.; Thuy, H.T.; Son, N.D.; Canh, D.G.; Hang, P.V.; Rao, M.; Field trial of a locally produced; killed; oral cholera vaccine in Vietnam. Lancet, 1997, 349 (9047), 231-235.
96. Kanungo, S.; Paisley, A.; Lopez, A. L; Bhattacharya, M.; Manna, B.; Kim, D.R.; Han, S.H.; Attridge, S.; Carbis, R.; Rao, R.; Holmgren, J.; Clemens, J. D.; Sur, D. Immune responses following one and two doses of the reformulated, bivalent, killed, wholecell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine, 2009, 27(49), 6887-6893.
97. Sur, D.; Lopez, A.L.; Kanungo, S.; Paisley, A.; Manna, B.; Ali, M.; Niyogi, S.K.; Park, J.K.; Sarkar, B.; Puri, M.K.; Kim, D.R.; Deen, J.L.; Holmgren, J.; Carbis, R.; Rao, R.; Nguyen T.V.; Donner, A.; Ganguly, N.K.; Nair, G.B.; Bhattacharya, S.K.; Clemens, J. D. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a clusterrandomized; double-blind; placebo-controlled trial. Lancet, 2009, 374(9702), 1694-1702.
98. Meeks, M.D.; Saksena, R.; Ma, X.; Wade, T.K.; Taylor, R.K.; Kovác, P.; Wade, W.F. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect Immun, 2004, 72(7), 4090-4101.
99. Gupta, R.K.; Szu, S.C.; Finkelstein, R.A.; Robbins, J.B. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun, 1992, 60(8), 3201-3208.
100. Kabir, S. Preparation and immunogenicity of a bivalent cell-surface protein-polysaccharide conjugate of Vibrio cholerae. J Med Microbiol, 1987, 23(1), 9-18.
101. García, L.; Jidy, M.D.; García, H.; Rodríguez, B.L.; Fernández, R.; Año, G.; Cedré, B.; Valmaseda, T.; Suzarte, E.; Ramírez, M.; Pino, Y.; Campos, J.; Menéndez, J.; Valera, R.; González, D.; González, I.; Pérez, O.; Serrano, T.; Lastre, M.; Miralles, F.; Del Campo, J.; Maestre, J.L.; Pérez, J.L.; Talavera, A.; Pérez, A.; Marrero, K.; Ledón, T.; Fando, R. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun, 2005, 73(5), 3018-3024.
102. Benítez, J.A.; García, L.; Silva, A.; García, H.; Fando, R.; Cedré, B.; Pérez, A.; Campos, J.; Rodríguez, B.L.; Pérez, J.L.; Valmaseda, T.; Pérez, O.; Pérez, A.; Ramírez, M.; Ledón, T.; Jidy, M.D.; Lastre, M.; Bravo, L.; Sierra, G. Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/ protease-defective El Tor strain as a cholera vaccine candidate. Infect Immun, 1999, 67(2), 539-545.
103. Mahalanabis, D.; Ramamurthy, T.; Nair, G.B.; Ghosh, A.; Shaikh, S.; Sen, B.; Thungapathra, M.; Ghosh, R.K.; Pazhani, G.P.; Nandy, R.K.; Jana, S.; Bhattacharya, S.K. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine, 2009, 27(35), 4850-4856.
104. Liang, W.; Wang, S.; Yu, F.; Zhang, L.; Qi, G.; Liu, Y.; Gao, S.; Kan, B. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun, 2003, 71(10), 5498-5504.
105. Schild, S.; Nelson, E.J.; Bishop, A.L.; Camilli, A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun, 2009, 77(1), 472-484.
106. Schild, S.; Nelson, E.J.; Camilli, A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun, 2008, 76(10), 4554-4563.
107. Roy, N.; Barman, S.; Ghosh, A.; Pal, A.; Chakraborty, K.; Das, S.S.; Saha, D.R.; Yamasaki, S.; Koley, H. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol, 2010, 60(1), 18-27.
108. Eko, F.O.; Schukovskaya, T.; Lotzmanova, E.Y.; Firstova, V.V.; Emalyanova, N.V.; Klueva, S.N.; Kravtzov, A.L.; Livanova, L.F.; Kutyrev, V.V.; Igietseme, J.U.; Lubitz, W.; Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine, 2003, 21(25-26), 3663-3674.
109. Acevedo, R.; Callicó, A.; del Campo, J.; González, E.; Cedré, B.; González, L.; Romeu, B.; Zayas, C.; Lastre, M.; Fernández, S.; Oliva, R.; García, L.; Pérez, J.L.; Pérez, O. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods, 2009, 49(4), 309-315.
110. Kirn, T.J.; Taylor, R.K. TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect Immun, 2005, 73(8), 4461-4470.
111. Osek, J.; Svennerholm, A.M.; Holmgren, J. Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili. Infect Immun. 1992, 60(11), 4961-4.
112. Sperandio, V.; Girón, J.A.; Silveira, W.D.; Kaper, J.B. The OmpU outer membrane protein; a potential adherence factor of Vibrio cholerae. Infect Immun, 1995, 63(11), 4433-4438.
113. Sinha, V.B.; Jacob, A.; Srivastava, R.; Kaper, J.B.; Srivastava, B.S. Identification of the flagellar antigens of Vibrio cholerae El Tor and their role in protection. Vaccine, 1993, 11(3), 372-375.
114. Jacob, A.; Sinha, V.B.; Sahib, M.K.; Srivastava, R.; Kaper, J.B.; Srivastava, B.S. Identification of a 33 kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae El Tor and its role in protection. Vaccine, 1993, 11(3), 376-382.